[go: up one dir, main page]

FR3090320B1 - Utilisation de la decorine dans le traitement du diabete - Google Patents

Utilisation de la decorine dans le traitement du diabete Download PDF

Info

Publication number
FR3090320B1
FR3090320B1 FR1873296A FR1873296A FR3090320B1 FR 3090320 B1 FR3090320 B1 FR 3090320B1 FR 1873296 A FR1873296 A FR 1873296A FR 1873296 A FR1873296 A FR 1873296A FR 3090320 B1 FR3090320 B1 FR 3090320B1
Authority
FR
France
Prior art keywords
diabetes
treatment
decorine
decorin
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1873296A
Other languages
English (en)
Other versions
FR3090320A1 (fr
Inventor
Karim Bouzakri
Michel Pinget
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Europeen dEtude du Diabete CEED
Original Assignee
Centre Europeen dEtude du Diabete CEED
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Europeen dEtude du Diabete CEED filed Critical Centre Europeen dEtude du Diabete CEED
Priority to FR1873296A priority Critical patent/FR3090320B1/fr
Priority to AU2019408887A priority patent/AU2019408887B2/en
Priority to IL284074A priority patent/IL284074B2/en
Priority to EP19848929.6A priority patent/EP3911356A1/fr
Priority to US17/416,130 priority patent/US12508301B2/en
Priority to PCT/FR2019/053186 priority patent/WO2020128351A1/fr
Publication of FR3090320A1 publication Critical patent/FR3090320A1/fr
Application granted granted Critical
Publication of FR3090320B1 publication Critical patent/FR3090320B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne de la décorine ou une composition comprenant de la décorine pour son utilisation dans le traitement du diabète, de type 1 (notamment dans le cadre d’une transplantation de cellules d’ilots pancréatiques), de type 2 ou du diabète gestationnel.
FR1873296A 2018-12-19 2018-12-19 Utilisation de la decorine dans le traitement du diabete Active FR3090320B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1873296A FR3090320B1 (fr) 2018-12-19 2018-12-19 Utilisation de la decorine dans le traitement du diabete
AU2019408887A AU2019408887B2 (en) 2018-12-19 2019-12-19 Decorin for use in the treatment of diabetes
IL284074A IL284074B2 (en) 2018-12-19 2019-12-19 Decorin for use in the treatment of diabetes
EP19848929.6A EP3911356A1 (fr) 2018-12-19 2019-12-19 La decorine pour son utilisation dans le traitement du diabete
US17/416,130 US12508301B2 (en) 2018-12-19 2019-12-19 Decorin for its use in the treatment of diabetes
PCT/FR2019/053186 WO2020128351A1 (fr) 2018-12-19 2019-12-19 La decorine pour son utilisation dans le traitement du diabete

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1873296A FR3090320B1 (fr) 2018-12-19 2018-12-19 Utilisation de la decorine dans le traitement du diabete

Publications (2)

Publication Number Publication Date
FR3090320A1 FR3090320A1 (fr) 2020-06-26
FR3090320B1 true FR3090320B1 (fr) 2023-03-03

Family

ID=66530256

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1873296A Active FR3090320B1 (fr) 2018-12-19 2018-12-19 Utilisation de la decorine dans le traitement du diabete

Country Status (5)

Country Link
EP (1) EP3911356A1 (fr)
AU (1) AU2019408887B2 (fr)
FR (1) FR3090320B1 (fr)
IL (1) IL284074B2 (fr)
WO (1) WO2020128351A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0616536B1 (fr) * 1991-12-04 1999-03-17 La Jolla Cancer Research Foundation Utilisation de décorine ou de biglycane pour la fabrication d'un médicament destiné au traitement de la pathologie associée au diabète
ATE390931T1 (de) * 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
KR20120114282A (ko) * 2009-12-04 2012-10-16 유클리드 시스템스 코포레이션 황반변성, 당뇨망막병증 및 당뇨 황반부종의 예방 및 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
AU2019408887B2 (en) 2025-11-27
IL284074B2 (en) 2025-07-01
IL284074A (en) 2021-08-31
US20220072106A1 (en) 2022-03-10
AU2019408887A1 (en) 2021-08-12
IL284074B1 (en) 2025-03-01
WO2020128351A1 (fr) 2020-06-25
EP3911356A1 (fr) 2021-11-24
FR3090320A1 (fr) 2020-06-26

Similar Documents

Publication Publication Date Title
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
EA202190983A1 (ru) Новое антитело к с-kit
MA47399A (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MX2021013713A (es) Celulas pluripotentes modificadas.
MA67726B1 (fr) Utilisations thérapeutiques de dérivés deutérés du lanifibranor
BR112019023290A2 (pt) Tienopiridinas e benzotiofenos úteis como inibidores de irak4
EA202092489A1 (ru) СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ
FR3046421B1 (fr) Procede de fabrication de substituts cutanes par depot additif
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
PE20210372A1 (es) Inhibidores de proteina tirosina fosfatasa y sus metodos de uso
MA33339B1 (fr) Utilisation d'un anticorps anti-tau ps422 pour le traitement de maladies cérébrales
MA45655A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
CO2020000584A2 (es) Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso
EP1921917A4 (fr) Aminopiperidines fusionnees utilisees comme inhibiteurs de dipeptidyl-peptidase-iv pour le traitement ou la prevention du diabete
PH12021500012A1 (en) Inhibitors of keapi-nrf2 protein-protein interaction
JOP20210298A1 (ar) طرق وتركيبات للوقاية من مرض السكري من النوع الأول
MA52216B1 (fr) Mirikizumab pour le traitement de la colite ulcéreuse
EA202090513A1 (ru) Агенты, модулирующие функции бета-катенина, и связанные способы
MA46548B1 (fr) Fsh pour le traitement de l'infertilité
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
FR3090320B1 (fr) Utilisation de la decorine dans le traitement du diabete
MA54511B1 (fr) Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire
FR3034418A1 (fr) Utilisation de combinaisons particulieres de carbohydrates pour stabiliser des proteines, et compositions proteiques contenant de telles combinaisons
MA45609B1 (fr) Compositions d'acide cromoglicique pour le traitement de la dermatite
FR3074421B1 (fr) Extrait d'helichrysum gymnocephalum pour le traitement et/ou la prevention des dermatoses inflammatoires

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200626

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7